Detalles de la búsqueda
1.
Social contact and the perceived impact of social distancing on health outcomes during the COVID-19 pandemic among community dwelling older adults taking part in the OPAL cohort study.
BMC Public Health
; 24(1): 1510, 2024 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38840093
2.
Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.
Antimicrob Agents Chemother
; 64(4)2020 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32015049
3.
Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.
Eur J Clin Pharmacol
; 76(3): 349-361, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31836928
4.
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30670413
5.
In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections.
Antimicrob Agents Chemother
; 62(7)2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29686147
6.
Avibactam Pharmacokinetic/Pharmacodynamic Targets.
Antimicrob Agents Chemother
; 62(6)2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29610208
7.
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30061279
8.
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
J Antimicrob Chemother
; 73(9): 2519-2523, 2018 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29912399
9.
In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
Antimicrob Agents Chemother
; 61(2)2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27872067
10.
In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
J Antimicrob Chemother
; 72(5): 1396-1399, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28088768
11.
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Clin Infect Dis
; 63(6): 754-762, 2016 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27313268
12.
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Clin Infect Dis
; 62(11): 1380-1389, 2016 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26962078
13.
Autocorrelation and cross-correlation between hCGß and PAPP-A in repeated sampling during first trimester of pregnancy.
Clin Chem Lab Med
; 51(9): 1781-8, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23612665
14.
Reply to Johnson.
Clin Infect Dis
; 64(3): 391, 2017 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27941118
15.
The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens.
Open Forum Infect Dis
; 9(7): ofac266, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35854983
16.
Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
Drug Saf
; 43(8): 751-766, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32602065
17.
Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial.
Pediatr Infect Dis J
; 38(8): 816-824, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31306396
18.
Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial.
Pediatr Infect Dis J
; 38(9): 920-928, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31335570
19.
Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers.
Drugs R D
; 18(3): 221-230, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30054895
20.
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Lancet Infect Dis
; 16(6): 661-673, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27107460